Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc.

FHTX · Nasdaq

Foghorn Therapeutics Inc. (FHTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Foghorn Therapeutics Inc. in 2026. The next earnings report is expected on November 10, 2026.

Earnings calendar

Next earnings date

10 Nov 2026

In 83 days

EPS estimate

-0.24

Revenue estimate

7.1M

Past earnings

06 Aug 2026
EPS actual
-0.10 (+59.2%)
estimate -0.25
Revenue actual
16.1M (+136.6%)
estimate 6.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
-0.29 (+4.9%)
estimate -0.31
Revenue actual
3.3M (-58.9%)
estimate 7.9M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
11 Mar 2026
EPS actual
-0.35 (-32.6%)
estimate -0.26
Revenue actual
9.2M (-14.3%)
estimate 10.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
05 Nov 2025
EPS actual
-0.25 (+25.0%)
estimate -0.33
Revenue actual
8.2M (+31.7%)
estimate 6.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Foghorn Therapeutics beat consensus estimates in its latest earnings report, with EPS of -$0.10 versus an estimate of -$0.245 and revenue of $16.1 million, 136.6% above expectations. In the previous report EPS also came in ahead of expectations while revenue fell short of estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Adrian H. Gottschalk
Employees
112
IPO date
23 Oct 2020
ISIN
US3441741077
Website
foghorntx.com

Frequently asked questions

When does Foghorn Therapeutics Inc. (FHTX) next report earnings?

Foghorn Therapeutics Inc. (FHTX) is scheduled to report earnings on November 10, 2026.

What was Foghorn Therapeutics Inc.'s most recent earnings date?

Foghorn Therapeutics Inc. (FHTX) last reported earnings on August 6, 2026.

Where is Foghorn Therapeutics Inc. stock listed?

Foghorn Therapeutics Inc. (FHTX) is listed on Nasdaq.